<p><img src="https://imageproxy.pbkrs.com/https://www.pharmaceutical-technology.com/wp-content/uploads/sites/24/2026/04/PT-02-04-2026-shutterstock_1836507013-430x241.jpg?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" width="430" height="241" original-src="https://imageproxy.pbkrs.com/https://www.pharmaceutical-technology.com/wp-content/uploads/sites/24/2026/04/PT-02-04-2026-shutterstock_1836507013-430x241.jpg"/></p>
<p>此次合作旨在支持新型抗體治療藥物，並加速有前景的分子進入臨牀和商業階段。圖片來源：Michele Ursi / Shutterstock.com。</p>
<p>百奧賽圖已與四環醫藥達成戰略合作，以推動多個疾病領域的新療法，包括減肥。</p>
<p>根據協議，百奧賽圖的全人源抗體發現平台將與四環醫藥在藥物開發、生產和商業化方面的能力相結合。</p>
<h3>深入瞭解 GlobalData</h3>
<ul>
<li><img src="/wp-content/themes/goodlife-wp-B2B/assets/img/report.png" alt="ReportsLogo" original-src="/wp-content/themes/goodlife-wp-B2B/assets/img/report.png"/></li>
</ul>
<p>報告</p>
<h4>LOA 和 PTSR 模型 - BI-907828 在去分化脂肪肉瘤中的應用</h4>
<ul>
<li><img src="/wp-content/themes/goodlife-wp-B2B/assets/img/report.png" alt="ReportsLogo" original-src="/wp-content/themes/goodlife-wp-B2B/assets/img/report.png"/></li>
</ul>
<p>報告</p>
<h4>LOA 和 PTSR 模型 - BI-907828 在肺腺癌中的應用</h4>
<h5>深入瞭解 GlobalData</h5>
<p>商業智能的黃金標準。</p>
<p>瞭解更多</p>
<p><img src="https://imageproxy.pbkrs.com/https://www.pharmaceutical-technology.com/wp-content/themes/goodlife-wp-B2B/assets/images/GMS-logo.svg?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://www.pharmaceutical-technology.com/wp-content/themes/goodlife-wp-B2B/assets/images/GMS-logo.svg"/></p>
<h4>發現高效的 B2B 營銷</h4>
<p>結合商業智能和編輯卓越，覆蓋 36 個領先媒體平台的專業人士。</p>
<p>瞭解更多</p>
<p>此次合作將專注於多個疾病領域的先進療法，包括減肥，利用公司的互補能力支持開發和潛在市場進展。</p>
<p>百奧賽圖將利用其綜合平台，包括體內有效性系統、靶向人源化小鼠模型和基於 AI 的抗體發現平台，這些平台是基於真實人類抗體序列開發的。</p>
<p>這種方法旨在支持新型抗體治療藥物的開發，並加速有前景的分子進入臨牀和商業階段。</p>
<p>百奧賽圖總裁兼首席執行官沈躍雷博士表示：“我們很高興與四環醫藥建立這一戰略合作關係。</p>
<p>“此次合作將進一步擴大我們在多種疾病領域的聯合努力，並進一步展示我們技術平台在行業中的強大認可。”</p>
<p>百奧賽圖專注於利用基因編輯技術研發基於抗體的藥物。</p>
<p>該公司建立了一個雙引擎平台，結合了全人源抗體庫和靶向人源化小鼠模型組合，以支持全球藥物發現和開發。</p>
<p>通過其 RenSuper Biologics 子品牌，百奧賽圖還提供了一個現成的庫，包含超過一百萬個針對 1000 多個靶點的全人源抗體序列。</p>
<p>在 2024 年 1 月，百奧賽圖與 Radiance Biopharma 簽署了獨家選擇和許可協議，用於雙特異性抗體藥物偶聯物（BsADC）。</p>

華夏中證生物科技主題ETF

華夏醫藥ETF

百奧賽圖-B

<p>百奧賽圖已與四環醫藥建立合作關係，共同開發新療法，重點關注減肥及其他疾病領域。此次合作將百奧賽圖的人類抗體發現平台與四環的藥物開發和商業化專業知識相結合。該戰略聯盟旨在加速有前景的抗體療法的臨牀和商業進展，利用先進技術和綜合平台。百奧賽圖首席執行官沈躍雷博士對這一合作表示熱情，強調其在藥物發現和開發方面增強雙方共同努力的潛力</p>

<p><img src="https://imageproxy.pbkrs.com/https://www.pharmaceutical-technology.com/wp-content/uploads/sites/24/2026/04/PT-02-04-2026-shutterstock_1836507013-430x241.jpg" alt="" original-src="https://www.pharmaceutical-technology.com/wp-content/uploads/sites/24/2026/04/PT-02-04-2026-shutterstock_1836507013-430x241.jpg"/></p>
<p>The collaboration is intended to support new antibody therapeutics and accelerate promising molecules towards clinical and commercial stages. Credit: Michele Ursi / Shutterstock.com.</p>
<div class="lb-trans"><p>此次合作旨在支持新型抗體治療藥物，並加速有前景的分子進入臨牀和商業階段。圖片來源：Michele Ursi / Shutterstock.com。</p>
</div><p>Biocytogen has entered a strategic partnership with Sihuan Pharmaceutical to advance new therapeutics across several disease areas, including weight loss.</p>
<div class="lb-trans"><p>百奧賽圖已與四環醫藥達成戰略合作，以推動多個疾病領域的新療法，包括減肥。</p>
</div><p>Under the agreement, Biocytogen’s fully human antibody discovery platform will be combined with Sihuan Pharmaceutical’s capabilities in drug development, manufacturing, and commercialisation.</p>
<div class="lb-trans"><p>根據協議，百奧賽圖的全人源抗體發現平台將與四環醫藥在藥物開發、生產和商業化方面的能力相結合。</p>
</div><h3>Go deeper with GlobalData</h3>
<div class="lb-trans"><h3>深入瞭解 GlobalData</h3>
</div><ul>
<li><img src="/wp-content/themes/goodlife-wp-B2B/assets/img/report.png" alt="ReportsLogo" original-src="/wp-content/themes/goodlife-wp-B2B/assets/img/report.png"/></li>
</ul>
<div class="lb-trans"><ul>
<li><img src="/wp-content/themes/goodlife-wp-B2B/assets/img/report.png" alt="ReportsLogo" original-src="/wp-content/themes/goodlife-wp-B2B/assets/img/report.png"/></li>
</ul>
</div><p>Reports</p>
<div class="lb-trans"><p>報告</p>
</div><h4>LOA and PTSR Model - BI-907828 in Dedifferentiated Liposarcoma</h4>
<div class="lb-trans"><h4>LOA 和 PTSR 模型 - BI-907828 在去分化脂肪肉瘤中的應用</h4>
</div><ul>
<li><img src="/wp-content/themes/goodlife-wp-B2B/assets/img/report.png" alt="ReportsLogo" original-src="/wp-content/themes/goodlife-wp-B2B/assets/img/report.png"/></li>
</ul>
<div class="lb-trans"><ul>
<li><img src="/wp-content/themes/goodlife-wp-B2B/assets/img/report.png" alt="ReportsLogo" original-src="/wp-content/themes/goodlife-wp-B2B/assets/img/report.png"/></li>
</ul>
</div><p>Reports</p>
<div class="lb-trans"><p>報告</p>
</div><h4>LOA and PTSR Model - BI-907828 in Lung Adenocarcinoma</h4>
<div class="lb-trans"><h4>LOA 和 PTSR 模型 - BI-907828 在肺腺癌中的應用</h4>
</div><h5>Go deeper with GlobalData</h5>
<div class="lb-trans"><h5>深入瞭解 GlobalData</h5>
</div><p>The gold standard of business intelligence.</p>
<div class="lb-trans"><p>商業智能的黃金標準。</p>
</div><p>Find out more</p>
<div class="lb-trans"><p>瞭解更多</p>
</div><p><img src="https://imageproxy.pbkrs.com/https://www.pharmaceutical-technology.com/wp-content/themes/goodlife-wp-B2B/assets/images/GMS-logo.svg" alt="" original-src="https://www.pharmaceutical-technology.com/wp-content/themes/goodlife-wp-B2B/assets/images/GMS-logo.svg"/></p>
<h4>Discover B2B Marketing That Performs</h4>
<div class="lb-trans"><h4>發現高效的 B2B 營銷</h4>
</div><p>Combine business intelligence and editorial excellence to reach engaged professionals across 36 leading media platforms.</p>
<div class="lb-trans"><p>結合商業智能和編輯卓越，覆蓋 36 個領先媒體平台的專業人士。</p>
</div><p>Find out more</p>
<div class="lb-trans"><p>瞭解更多</p>
</div><p>The collaboration will focus on advanced therapies in multiple disease areas, including weight loss, using the companies’ complementary capabilities to support development and potential market progress.</p>
<div class="lb-trans"><p>此次合作將專注於多個疾病領域的先進療法，包括減肥，利用公司的互補能力支持開發和潛在市場進展。</p>
</div><p>Biocytogen will utilise its integrated platforms, including in vivo efficacy systems, target-humanised mouse models, and an AI-based antibody discovery platform developed from real human antibody sequences.</p>
<div class="lb-trans"><p>百奧賽圖將利用其綜合平台，包括體內有效性系統、靶向人源化小鼠模型和基於 AI 的抗體發現平台，這些平台是基於真實人類抗體序列開發的。</p>
</div><p>This approach is intended to support the development of new antibody therapeutics and accelerate promising molecules towards clinical and commercial stages.</p>
<div class="lb-trans"><p>這種方法旨在支持新型抗體治療藥物的開發，並加速有前景的分子進入臨牀和商業階段。</p>
</div><p>Biocytogen president and CEO Dr Yuelei Shen said: “We are pleased to establish this strategic partnership with Sihuan Pharmaceutical.</p>
<div class="lb-trans"><p>百奧賽圖總裁兼首席執行官沈躍雷博士表示：“我們很高興與四環醫藥建立這一戰略合作關係。</p>
</div><p>“This collaboration will further expand our joint efforts across diverse disease areas and further demonstrate strong industry recognition of our technology platforms.”</p>
<div class="lb-trans"><p>“此次合作將進一步擴大我們在多種疾病領域的聯合努力，並進一步展示我們技術平台在行業中的強大認可。”</p>
</div><p>Biocytogen is focused on the research and development of antibody-based drugs using gene editing technology.</p>
<div class="lb-trans"><p>百奧賽圖專注於利用基因編輯技術研發基於抗體的藥物。</p>
</div><p>The company has established a dual-engine platform that combines a fully human antibody library with a target-humanised mouse model portfolio to support global drug discovery and development.</p>
<div class="lb-trans"><p>該公司建立了一個雙引擎平台，結合了全人源抗體庫和靶向人源化小鼠模型組合，以支持全球藥物發現和開發。</p>
</div><p>Through its RenSuper Biologics sub-brand, it also offers an off-the-shelf library of more than a million fully human antibody sequences against over 1,000 targets.</p>
<div class="lb-trans"><p>通過其 RenSuper Biologics 子品牌，百奧賽圖還提供了一個現成的庫，包含超過一百萬個針對 1000 多個靶點的全人源抗體序列。</p>
</div><p>In January 2024, Biocytogen and Radiance Biopharma signed an exclusive option and licence agreement for a bispecific antibody-drug conjugate (BsADC).</p>
<div class="lb-trans"><p>在 2024 年 1 月，百奧賽圖與 Radiance Biopharma 簽署了獨家選擇和許可協議，用於雙特異性抗體藥物偶聯物（BsADC）。</p>
</div>

百奧賽圖與四環醫藥合作推進減肥新療法的研發